Indian cabinet allows Lithium's commercial mining to charge up it's EV ambitions

Indian Cabinet approved amendments to the Mines and Minerals (Development and Regulation) Act, 1957, on July 12, allowing for mining of lithium and other minerals, ET reported citing sources.

It was widely reported earlier  that the government was planning to amend the  act to encourage exploration of deep-seated minerals   such  as tellurium, selenium, lead, zinc, cadmium, indium, gold, silver, diamond, rock phosphate, apatite, potash, and elements of the rare earth group.

Critical and strategic minerals such as lithium, cobalt, molybdenum, rhenium, tungsten, graphite, vanadium, nickel, tin, platinum  etc.   Group of elements like  columbite, tantalite, lepidolite, scheelite and cassiterite are also part of the list.

The amendment proposed to insert the provision of an exploration licence in the law which will be granted through auction for undertaking reconnaissance and prospecting operations, according to an official.

Companies will be allowed to suggest areas they want to explore, and eventually mine in India, as per the changes. This is a deviation from the usual practice where blocks or mines are defined by the government to be taken up for auction.

The licence will also be granted only for deep-seated and critical minerals that will be specified in a new schedule to the Act, said the official.

The changes are likely to incentivise private sector participation in all spheres of mineral exploration, with a focus on precious and critical ones. They will allow junior mining companies to get exploration rights on the basis of available baseline survey data. These companies explore the area from the reconnaissance stage and bring it up to the level required for starting mining operations.

Companies will also be allowed to transfer the mineral concession in full or part during the exploration period or at the conclusion of exploration, as per the changes.

 

Source : ET India (Reproduced with edited version)

 

Lithium finding in India , EV industry Charged Up..

As India gears up to boost electric vehicle (EV) adoption, the massive find of lithium reserves in the country has built up  excitement , hope of self-Reliance & brightened up the prospects for the country in the field of EV battery cell manufacturing. 

According to the Council on Energy, Environment and Water (CEEW), the country will require USD 4.5Billion of investment to meet its domestic lithium-ion battery manufacturing target of setting up 50 GWh of lithium-ion cell and battery manufacturing plants. India's lithium cell production is projected to be 900 GWh by 2030.  

 "The 5.9 million tonnes of lithium reserves found in J&K, If completely extracted and converted into battery-grade Lithium  salts can support up to  great extent   though  the   details about quality, nature etc are yet to be fully established.

Lithium is  the lightest  metal & lightest  solid element . Being highly reactive   not found in its elemental form.  Mostly found in concentration with other materials in the form of oxides and carbonates. Extracting & converting the raw lithium to battery-grade lithium calls for a series of refining processes some of  technology are not available  in India. Very few Global companies  have  such expertise  and being doing this for decades.  

Though the EV penetration in India  till 2020  was very small , the EV penetration in India is slowly but steadily increasing, especially in the e-scooter segment. Now, the four-wheeler manufacturers have also joined the bandwagon,  specially Tata Motors  , M&M pushing India's aim to significantly cut the dependency on traditional fuels and internal combustion engine-driven vehicles by 2030.  

The slogan EV30@30  which means ,  the government expects the EV sales penetration to be 30 per cent by 2030. for private automobiles. 70 per cent for commercial vehicles, and 80 per cent for two and three-wheelers, which would not only reduce the country's oil import bills in the longer term, but also ensure a cleaner environment.  

The discovery of Lithium is vital as it comes at a time when India is going all out for a green transition in transportation,, where electric vehicle adoption has become a national priority..

India finds 5.9 million tonnes of Lithium deposits.

The Union Government of India on Thursday said that 5.9 million tonnes of lithium reserves have been found for the first time in the country in Jammu and Kashmir. Lithium is a non-ferrous metal and is one of the key components in EV batteries.

"Geological Survey of India for the first time established Lithium inferred resources (G3) of 5.9 million tonnes in the Salal-Haimana area of the Reasi district of Jammu and Kashmir," the Ministry of Mines said on Thursday.

It further said that 51 mineral blocks including Lithium and Gold were handed over to respective state governments.

"Out of these 51 mineral blocks, 5 blocks pertain to gold and other blocks pertain to commodities like potash, molybdenum, base metals etc. spread across 11 states of Jammu and Kashmir (UT), Andhra Pradesh, Chhattisgarh, Gujarat, Jharkhand, Karnataka, Madhya Pradesh, Odisha, Rajasthan, Tamil Nadu, and Telangana," the ministry added.

The blocks were prepared based on the work carried out by GSI from field seasons 2018-19 to till date.

FMC Corporation Announces Acquisition of Significant Portion of DuPont’s Crop Protection Business; Simultaneous Sale of Health and Nutrition to DuPont

FMC Corporation (NYSE: FMC) and DuPont (NYSE: DD)  announced the signing of a definitive agreement for FMC to acquire the portion of DuPont's Crop Protection business it must divest to comply with the European Commission ruling related to its merger with The Dow Chemical Company.  Additionally, DuPont will acquire FMC Health and Nutrition and receive $1.2 billion in cash.  FMC will acquire DuPont's global chewing pest insecticide portfolio, its global cereal broadleaf herbicides, and a substantial portion of DuPont's global crop protection R&D capabilities.  In 2017, FMC expects this acquired business will generate approximately $1.5 billion in revenue and $475 million of EBITDA.

After closing of the acquisition, FMC Agricultural Solutions will become the fifth largest crop protection chemical company in the world by revenue, with estimated annual revenue of approximately $3.8 billion. 

The Crop Protection Business Being Acquired

The acquired portion of DuPont's crop protection business includes an industry-leading selective insecticide portfolio consisting of Rynaxypyr^®, Cyazypyr^® and Indoxacarb.  The first two of these products have full patent protection over their respective active ingredients, and FMC expects these products will generate over $1 billion in 2017 revenue.  These selective insecticides are highly complementary to FMC's existing broad spectrum insecticide portfolio. 

The acquired portfolio also includes DuPont's global cereal broadleaf herbicides, consisting of nine active ingredients and multiple formulated products.  This herbicide portfolio comes with strong, recognized brands and DuPont's proprietary PrecisionPac^® technology.  These products bring significant diversification to FMC's crop exposure in herbicides, as well as increasing the balance of pre-emergent and post-emergent applications in FMC's portfolio.

The geographic spread of the revenue in this portfolio will result in a significant increase in FMC's presence in Asia and Europe.  Following the acquisition, FMC's crop protection revenue will be almost equally spread across all four major regions – North America, Latin America, Europe and Asia.

The underlying intellectual property related to the acquired products, including patents, registrations and data packages, will be transferred to FMC.  FMC will acquire a global manufacturing network to fully support these products, including four active ingredient manufacturing facilities and 10 regional formulation plants.

The acquisition will bring DuPont's world-class discovery and development organization, including its Delaware crop protection research headquarters, 14 regional development labs and related regulatory capabilities.  This organization includes a pipeline of 15 synthetic active ingredients currently in development, covering insecticides, herbicides and fungicides, and an extensive library of 1.8 million synthetic compounds.  The majority of DuPont's crop protection research workforce will transfer to FMC as part of this transaction.

FMC Health and Nutrition Divestiture

FMC Health and Nutrition will become part of DuPont's Nutrition & Health segment. 

"FMC Health and Nutrition is a highly profitable business with leading positions across the vast majority of its portfolio, deep applications knowledge and an extensive global network of laboratories and manufacturing facilities.  It is a very complementary fit with DuPont's current portfolio.  We are confident it will thrive under DuPont's leadership and will contribute to their successful Nutrition & Health business," said Brondeau.

Additional Information

The transaction is subject to the closing of the Dow and DuPont merger, as well as customary closing conditions and regulatory approvals.  Closing is expected to occur in the fourth quarter of 2017.  FMC expects this transaction to be immediately accretive to adjusted earnings per share, and will give updated guidance for 2017 at its earnings call scheduled for May 2, 2017.  

Dyal Co. LLC and Citi acted as financial advisors and Wachtell, Lipton, Rosen & Katz acted as legal counsel to FMC.  Citi provided financing advice and committed debt facilities.

source : FMC website

Bayer and Monsanto to Create a Global Leader in Agriculture

In the largest deal of 2016 (so far), after months of negotiations  with several  baby steps  agriculture giants Bayer and Monsanto announced  that  they are planning to merge. In an  all-cash   transaction    Bayer  striking the deal a $128  a share  valuing Monsanto at $66B.  including the debt.

Consolidation has been driven by a global  glut that has pushed down crop prices and hurt farm incomes, leading to reduced investment in agricultural inputs such as fertilisers and  Agrochemicals.   Several Mega & small mergers are right now underway/partially completed   like Dow Chemical and DuPont, ChemChina &   Syngenta, FMC & Cheminova  etc.

But the proposed merger  likely face an intense and lengthy regulatory process If the deal closes, it will create a company commanding more than a quarter of the combined world market for seeds and pesticides in the fast-consolidating farm supplies industry.

Both the   company executives claims the  businesses are complimentary & there is very little overlap between them.  However antitrust experts have said regulators  likely  demand the sale of some soybeans, cotton and canola seed assets.

The transaction includes a $2-billion break-up fee that Bayer will pay to Monsanto should it fail to get regulatory clearance. Bayer expects the deal to close by the end of 2017.

CRISIL rings Warning Bell for Indian Pharma Companies

A new Crisil report  made it clear how fast the Indian pharma sector needs to shift away from export-oriented manufacture of generics and the just process improvement  exercise, towards investing in R&D to develop new molecules and biosimilars  

Sellers of copycat drugs in developed markets may see exports fall by 10-12% in the next five years as fewer drugs go off-patent in these markets,  compare to  CAGR  of 19% seen in the last decade. CRISIL Research said. The deceleration likely to be much more post 2020.

Between 2011 and 2015, Indian companies accounted for an average of 37% of all abbreviated new drug application (ANDA) approvals—which enable a company to sell generic versions of innovator molecules —in the US market. This was about  similar   to 40%  share held by US companies, but way ahead of the next competing countries—Israel and Germany—which had 5% each.

Non availability of any   further off patent  block buster  and  fall  in growth rate  of   US generic market, the writing on the wall for Indian drug-makers is clear: They have to move up the value-chain, from making cheap copies of off-patent drugs to creating and owning intellectual property through new discovery and biosimilars. To be sure, they have increased R&D spending significantly over the years. Top 30 companies research spending was 6.5% of revenues in FY15, compared to 3.8%  a decade back. However, this pales in comparison with global majors, who spend close to 16%.

Moreover, the Crisil report points out, much of the Indian companies’ expenditure is  for launching generic therapies, changing product mix in generics, and process development. Besides, the atmosphere of doubt over drug quality—in the wake of the FDA’s crackdown—further dampens Indian generic-makers’ export-prospects. 

CRISIL Research analysis indicates that 14  Indian companies together have 39 products in various stages of clinical development. These companies have adopted various approaches—such as in-house development, joint development and out-licensing—to manage the risk-return trade-off.  However, no one has launched a new molecule in a regulated market such as the US.

Thus far,  it is  disappointing in NCE effort  but  39 product in the pipeline should be an encouraging sign for Indian pharma’s prospects. The key challenge will be to uphold drug-quality and pass the approval hurdles in well-regulated jurisdictions like the US.